Transdermal lisuride delivery in the treatment of Parkinson's disease.
Transdermal delivery of dopamine agonists (DA) is a promising therapeutic concept, which aims to ameliorate frequency and intensity of motor fluctuations in patients with Parkinson's disease (PD). We treated 8 PD patients with unpredictable on-off phenomena with lisuride patches (release: 2-5 microg lisuride base/cm2/hour in mice) in addition to their preexisting antiparkinsonian drug regime up to a period of 8 days. In order to quantify the intensity and frequency of motor fluctuations, we determined the motor changing rate (MCR), which corresponds to the patient's self rating of motor function, performed every thirty minutes, divided through the number of scored intervals minus 1. Additional lisuride patch application significantly (p = 0.023) improved the MCR compared to baseline. Relevant side effects were transient skin irritations in four patients. Our observational study demonstrates the safety, tolerability and efficacy of transdermal lisuride delivery in the treatment of motor complications.
Woitalla
D
D
Department of Neurology, St Josef Hospital, Ruhr University Bochum, Germany. dirk.woitalla@ruhr-uni-bochum.de
Müller
T
T
Benz
S
S
Horowski
R
R
Przuntek
H
H
D000279:Administration, Cutaneous; D000368:Aged; D000704:Analysis of Variance; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D006801:Humans; D016014:Linear Models; D008090:Lisuride / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010865:Pilot Projects
D008090:Lisuride